Literature DB >> 8982048

Thrombocytosis in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment.

R Losada1, E Espinosa, C Hernández, E Dorticos, P Hernández.   

Abstract

In 26 acute promyelocytic leukaemia (APL) patients treated with all-trans retinoic acid (ATRA), 23% had platelet counts between 459 and 800 x 10(9)/I during treatment. These values, observed between days 28 and 45 of ATRA treatment, were transient and asymptomatic. We report two APL cases with platelet counts > 1000 x 10(9)/I during ATRA therapy who were treated with recombinant interferon alpha. In both cases ATRA doses were not modified, no complications secondary to thrombocytosis were seen, and they subsequently achieved complete remission. It is suggested that IL-6 may play an important role in the pathogenesis of the thrombocytosis induced by ATRA. To our knowledge, this is the first report of thrombocytosis occurring during ATRA treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982048     DOI: 10.1046/j.1365-2141.1996.d01-1953.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis.

Authors:  Rui Vilar; Samuel W Lukowski; Marco Garieri; Corinne Di Sanza; Marguerite Neerman-Arbez; Richard J Fish
Journal:  Thromb Haemost       Date:  2020-12-10       Impact factor: 5.249

2.  Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide.

Authors:  Maryam Habibi; Reza Manouchehri Ardekani; Hossein Motedayyen
Journal:  Clin Case Rep       Date:  2021-02-24

Review 3.  Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment.

Authors:  Mohmood B Aldapt; Nancy Kassem; Randa Al-Okka; Rula Ghasoub; Dina Soliman; Mohammad A Abdulla; Deena Mudawi; Feryal Ibrahim; Mohamed A Yassin
Journal:  Acta Biomed       Date:  2018-04-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.